Octreotide may have a marginal benefit by decreasing the rate of nonvariceal bleeding, but it is inferior to intravenous proton pump inhibitors. Octreotide is most useful in patients with variceal bleeding
If you want to change selection, open document below and click on "Move attachment"
pdf
owner:
ELBOMBARDO - (no access) - MKSAP_17.pdf, p2594
Summary
| status | not read | | reprioritisations | |
|---|
| last reprioritisation on | | | suggested re-reading day | |
|---|
| started reading on | | | finished reading on | |
|---|
Details